Contributions
Abstract: EP1446
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Objective: The aim of this study is two-fold:
(1) To investigate differences in amplitude of low-frequency fluctuations (ALFF) in resting state functional magnetic resonance imaging (rs-fMRI) among cohorts of subjects with multiple sclerosis (MS) stratified by progression, and
(2) To evaluate ALFF"s relation to anxiety and depression.
Methods: We prospectively studied consecutive patients with radiologically isolated syndrome or clinically isolated syndrome (n=23; 18 female; age 35±9.1 years), primary or secondary progressive (PP/PS) (n= 35; 19 female; age 53.5±7.2 years), relapsing-remitting (n= 24; 16 female; age 43.9±11.3 years) multiple sclerosis and 30 healthy controls (18 female; age 41.4±10.9 years) on a 1.5T scanner. Imaging included 10 minutes of rs-fMRI acquisition (TR=2.500ms; TE=50ms; flip angle=90º) and anatomic T1 turbo-field echo sequence. We used Data Processing Assistant for rs-fMRI running in Matlab® to compute and normalize ALFF maps, obtaining mean values from automated anatomic labelling regions of interest for statistical analysis. We calculated total white and grey matter volumes from anatomic T1 with Freesurfer. We used the Hospital Anxiety and Depression (HAD) scale to measure anxiety and depression. To avoid confounding effects of age or schooling on cognitive performance, we used unstandardized residual values of the regression between cognitive scores and these factors for all analyses. We used analysis of variance and Bonferroni test to assess differences between groups. To analyze the impact of ALFF on HAD score among groups, we used analysis of covariance (ANCOVA) on variables associated with cognitive scores (p< 0.05).
Results: HAD-depression subscale differed between PP/PS and controls (p< 0.018); no other differences in HAD scores were found between study groups. Differences in HAD-anxiety scores among groups were explained by mean ALFF in the left posterior cingulate gyrus (p=0.004). The best ANCOVA model to explain HAD-depression scores among groups (p< 0.001) included mean ALFF in the left mid cingulate (p=0.029), left inferior frontal gyrus (p=0.011), left medial frontal gyrus (p=0.001), and right superior temporal gyrus (p=0.033).
Conclusion: Our preliminary results suggest ALFF on rs-fMRI is associated with anxiety and depression scores in subjects with MS.
Disclosure:
Ll. Ramió-Torrentà has received speaking honoraria and travel expenses for scientific meetings and has participated in advisory boards in the past years with Bayer Schering Pharma, Biogen, EMD Merck Serono, Sanofi Genzyme, Novartis, Sanofi-Aventis, Teva Phramaceuticals, Almirall and Roche.
G. Blasco: nothing to disclose
C. Biarnés: nothing to disclose
J. Gich has received consulting fees from Novartis and speaking honoraria from Bayer Schering Pharma, Biogen, EMD Merck Serono, Novartis, Teva Phramaceuticals, Almirall.
M. Rivero: nothing to disclose
J. Salavedra: nothing to disclose
B. Beltran: nothing to disclose
P. Danius i Estadella: nothing to disclose
S. Pedraza: nothing to disclose
J. Puig: nothing to disclose
Funding: Novartis
Abstract: EP1446
Type: ePoster
Abstract Category: Pathology and pathogenesis of MS - Imaging
Objective: The aim of this study is two-fold:
(1) To investigate differences in amplitude of low-frequency fluctuations (ALFF) in resting state functional magnetic resonance imaging (rs-fMRI) among cohorts of subjects with multiple sclerosis (MS) stratified by progression, and
(2) To evaluate ALFF"s relation to anxiety and depression.
Methods: We prospectively studied consecutive patients with radiologically isolated syndrome or clinically isolated syndrome (n=23; 18 female; age 35±9.1 years), primary or secondary progressive (PP/PS) (n= 35; 19 female; age 53.5±7.2 years), relapsing-remitting (n= 24; 16 female; age 43.9±11.3 years) multiple sclerosis and 30 healthy controls (18 female; age 41.4±10.9 years) on a 1.5T scanner. Imaging included 10 minutes of rs-fMRI acquisition (TR=2.500ms; TE=50ms; flip angle=90º) and anatomic T1 turbo-field echo sequence. We used Data Processing Assistant for rs-fMRI running in Matlab® to compute and normalize ALFF maps, obtaining mean values from automated anatomic labelling regions of interest for statistical analysis. We calculated total white and grey matter volumes from anatomic T1 with Freesurfer. We used the Hospital Anxiety and Depression (HAD) scale to measure anxiety and depression. To avoid confounding effects of age or schooling on cognitive performance, we used unstandardized residual values of the regression between cognitive scores and these factors for all analyses. We used analysis of variance and Bonferroni test to assess differences between groups. To analyze the impact of ALFF on HAD score among groups, we used analysis of covariance (ANCOVA) on variables associated with cognitive scores (p< 0.05).
Results: HAD-depression subscale differed between PP/PS and controls (p< 0.018); no other differences in HAD scores were found between study groups. Differences in HAD-anxiety scores among groups were explained by mean ALFF in the left posterior cingulate gyrus (p=0.004). The best ANCOVA model to explain HAD-depression scores among groups (p< 0.001) included mean ALFF in the left mid cingulate (p=0.029), left inferior frontal gyrus (p=0.011), left medial frontal gyrus (p=0.001), and right superior temporal gyrus (p=0.033).
Conclusion: Our preliminary results suggest ALFF on rs-fMRI is associated with anxiety and depression scores in subjects with MS.
Disclosure:
Ll. Ramió-Torrentà has received speaking honoraria and travel expenses for scientific meetings and has participated in advisory boards in the past years with Bayer Schering Pharma, Biogen, EMD Merck Serono, Sanofi Genzyme, Novartis, Sanofi-Aventis, Teva Phramaceuticals, Almirall and Roche.
G. Blasco: nothing to disclose
C. Biarnés: nothing to disclose
J. Gich has received consulting fees from Novartis and speaking honoraria from Bayer Schering Pharma, Biogen, EMD Merck Serono, Novartis, Teva Phramaceuticals, Almirall.
M. Rivero: nothing to disclose
J. Salavedra: nothing to disclose
B. Beltran: nothing to disclose
P. Danius i Estadella: nothing to disclose
S. Pedraza: nothing to disclose
J. Puig: nothing to disclose
Funding: Novartis